PineBridge Investments’s Neurocrine Biosciences NBIX Stock Holding History

PineBridge Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$482K	Sell	2,860 -455	-14%	-$67.5K	﹤0.01%	479
2026 Q1	$437K	Buy	+3,315	New	+$440K	﹤0.01%	455
2025 Q2	–	Sell	-9,056	Closed	-$1M	–	683
2025 Q1	$1M	Sell	9,056 -21,059	-70%	-$2.67M	0.01%	500
2024 Q4	$4.11M	Sell	30,115 -227	-0.7%	-$28.1K	0.03%	348
2024 Q3	$3.5M	Buy	+30,342	New	+$4.16M	0.03%	363
2023 Q4	–	Sell	-12,399	Closed	-$1.39M	–	629
2023 Q3	$1.39M	Sell	12,399 -13,674	-52%	-$1.44M	0.02%	406
2023 Q2	$2.46M	Buy	26,073 +18,288	+235%	+$1.79M	0.03%	344
2023 Q1	$788K	Buy	+7,785	New	+$810K	0.01%	419

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PineBridge Investments's NBIX Position: Q2 2026 in Review

PineBridge Investments reduced its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, selling an estimated $67.5K and leaving 2,860 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #479.

PineBridge Investments first reported a position in NBIX in Q1 2023 and has held it in 8 quarters since. The position peaked at $4.11M in Q4 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

PineBridge Investments held 2,860 shares of Neurocrine Biosciences worth $482K as of Q2 2026.
PineBridge Investments sold 455 Neurocrine Biosciences shares in Q2 2026, an estimated $67.5K.
Neurocrine Biosciences made up ﹤0.01% of PineBridge Investments's portfolio in Q2 2026, its #479 holding.
PineBridge Investments first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 8 quarters since.
PineBridge Investments's Neurocrine Biosciences position peaked at $4.11M in Q4 2024.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on PineBridge Investments's 13F filing for Q2 2026, filed 14 Aug 2026.